CPT® Code 90715

Quick Reference: CPT 90715 (Tdap Vaccine, Age 7+)

• What CPT 90715 means: CPT 90715 reports the Tdap vaccine product (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis), for use in individuals 7 years or older, administered intramuscularly. It is the vaccine ingredient code; administration is billed separately.
• Do not confuse Tdap with Td: 90715 includes pertussis. 90714 is Td only (tetanus + diphtheria, no pertussis). Coding must match the actual product administered.
• 90718 is deleted: CPT 90718 (older Td code) was deleted effective January 1, 2013. If documentation shows Td was given, use the current Td product code (typically 90714) based on payer policy and product selection.
• Always bill a vaccine administration code: For most non-counseling adult/immunization encounters, use 90471 for the first injection and +90472 for each additional injection. For patients 18 or younger when physician/QHP counseling is documented, use 90460/90461 as appropriate.
• Diagnosis drives coverage (especially Medicare): Routine immunization encounters typically use Z23. When Tdap is given for wound management, documentation must support a specific injury/exposure diagnosis at the highest specificity and the claim should be built for the wound-care benefit pathway.
• Medicare Part B: narrow coverage rule: Medicare Part B generally pays tetanus-containing vaccines when medically necessary for an injury/wound, not as routine prevention. Many workflows require modifier AT for acute treatment on the vaccine and administration lines.
• CDC schedule anchors timing and "why": CDC's adult schedule indicates Td/Tdap boosters are given every 10 years; CDC also emphasizes Tdap during each pregnancy (optimal timing in weeks 27-36) to protect infants. These recommendations commonly align with commercial/Medicaid preventive coverage logic.
• Same-day E/M requires restraint: If a significant, separately identifiable E/M service occurs on the same date as immunization, apply modifier 25 to the E/M code (not to 90715 or 90471). Documentation must show work beyond routine vaccination screening/counseling.

CPT 90715 is a high-volume vaccine product code with predictable denial patterns. Most reimbursement and audit risk comes from a small number of avoidable failures: (1) billing the wrong product code (Tdap vs Td), (2) omitting the administration code (or using the wrong administration family for counseling), (3) misaligning diagnosis and coverage pathways -- especially Medicare Part B's wound-care rule, and (4) using modifier 25 reflexively without a separately identifiable E/M service. This 2026-focused guide standardizes CPT, ICD-10, modifier, and payer logic so claims are defensible and consistent with authoritative coding guidance and CDC recommendations.

1. Definition and Scope of CPT 90715

CPT 90715 reports the vaccine product commonly referred to as Tdap -- tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis -- used for individuals 7 years and older and administered intramuscularly. The key compliance concept is that 90715 is the product (ingredient) code. It does not represent the clinical work of giving the injection, monitoring the patient, documenting the vaccination record, or counseling. Those services are reported using immunization administration codes that must be chosen based on patient age and counseling documentation.

In routine operations, 90715 is typically used in three clinical contexts:

• Adolescents: a single dose during the adolescent schedule timing (often as the "Tdap booster").
• Adults: a one-time adult dose if never received, and then Td/Tdap boosters as recommended over the life course (often every 10 years).
• Pregnancy: CDC recommends a dose during each pregnancy, optimally in weeks 27 through 36 to maximize passive antibody transfer to the infant.

Compliance boundary: Tdap (90715) is defined for individuals 7 years and older. If documentation shows a patient younger than 7 received a pertussis-containing tetanus/diphtheria vaccine, coding must follow the actual product and the coding rules applicable to that age group. Do not "force fit" 90715 to resolve a workflow mismatch; reconcile the clinical product, inventory, and documentation instead.

2. Code Selection: 90715 vs 90714 and the Deleted 90718

2.1 90715 (Tdap) vs 90714 (Td): pertussis is the dividing line

The most common product-code error is confusing Tdap with Td. The CPT descriptors make the difference operationally clear: 90715 includes the acellular pertussis component; 90714 does not. Because payers increasingly validate immunization claims through record review and product verification workflows, the medical record should clearly identify which vaccine was administered (and ideally the manufacturer/lot), so the billed CPT code can be defended if questioned.

• Use 90715 when Tdap was administered (tetanus + reduced diphtheria + acellular pertussis).
• Use 90714 when Td was administered (tetanus + diphtheria only).

flowchart TD
    A[Tetanus-containing vaccine administered to patient age 7+] --> B{Which product was given?}
    B -->|Tdap: tetanus + diphtheria + pertussis| C[Bill 90715]
    B -->|Td: tetanus + diphtheria only| D[Bill 90714]
    B -->|Unknown / ambiguous documentation| E[STOP: Clarify product before coding]
    C --> F{Coverage pathway?}
    D --> F
    F -->|Routine immunization| G[Dx: Z23\nAdmin: 90471 first / +90472 additional]
    F -->|Medicare wound care / acute injury| H[Dx: Injury ICD-10 highest specificity\nAdmin: 90471 + modifier AT\nDocument wound and medical necessity]
    G --> I{Same-day E/M?}
    H --> I
    I -->|Yes, separately identifiable| J[Append modifier 25 to E/M code only]
    I -->|No separate E/M| K[Submit vaccine + admin codes only]

2.2 90718 is deleted: do not bill it

CPT 90718 was an older Td product code and is deleted effective January 1, 2013. It should not appear on current claims. In practice, the correct response to "90718-era workflow remnants" is not to resurrect a deleted code; it is to ensure that: (a) the administered product is documented correctly, (b) the appropriate current code is chosen (often 90714 when Td is used), and (c) inventory/build sheets are updated so staff do not chart outdated codes.

Audit risk: Billing a deleted CPT code is a high-friction error. Even when a payer denies quickly, repeated submission can create compliance exposure, rework cost, and credentialing scrutiny. Use the current product code that matches the administered vaccine, and keep your charge master and EHR picklists current.

3. Vaccine Administration Coding (90471-90472, 90460-90461)

Vaccine product coding answers "what was administered." Administration coding answers "what work was performed to administer it." CPT immunization administration coding is split by counseling and patient age. AAFP's administration guidance summarizes that: 90471/90472 are commonly used when there is no physician/QHP counseling component billed, while 90460/90461 are used for patients through age 18 when counseling by a physician or other qualified health care professional is documented.

3.1 Typical adult/non-counseling structure

• 90471: first vaccine administration (IM, SC, ID, etc.) in the encounter.
• +90472: each additional injection in the same encounter.

Example (adult, two injectable vaccines, no counseling billed):

• 90715 (Tdap product)
• 90471 (administration -- first injection)
• [Second vaccine product code]
• 90472 (administration -- additional injection)

3.2 Pediatric counseling structure (age 18 and under)

When a physician/QHP provides documented vaccine counseling to a patient through age 18, administration coding shifts to 90460/90461 logic. Importantly, these codes are component-based for combination vaccines, and proper use depends on documentation that counseling occurred. AAFP's guidance is the operational anchor for selecting the correct administration code family.

Common compliance mistake: Using counseling administration codes without counseling documentation, or defaulting to 90460/90461 for all pediatric immunizations. Your coding should follow the record: if counseling is not documented by a physician/QHP, use the non-counseling administration codes instead.

4. Diagnosis Coding and Coverage Pathways (Z23 vs Injury/Exposure)

Diagnosis coding determines which coverage pathway the claim is asking the payer to apply. For immunizations, two pathways dominate: (1) preventive/routine immunization, and (2) medically necessary administration for acute injury/wound care (particularly relevant to Medicare Part B).

4.1 Routine immunization: Z23 is the standard anchor

For routine vaccination encounters (no acute injury), practices typically use Z23 ("Encounter for immunization"). This aligns with common preventive claim structures and is frequently accepted across commercial and Medicaid plans when the vaccine is part of covered preventive benefits.

4.2 Wound care/acute injury: Medicare expects injury specificity

Medicare Part B is the payer category where diagnosis specificity is most likely to control payment outcomes for tetanus-containing vaccines. Noridian's Medicare guidance emphasizes that claims must include an injury diagnosis code of the highest specificity (including site and 7th character when required), and documentation must support the injury and the need for vaccination. In operational terms, a wound-care Tdap claim is built around the injury, not around Z23.

Practical Medicare rule: If your documentation and ICD-10 coding read like a routine booster (Z23-only), Medicare Part B processing will generally treat the vaccine as noncovered under Part B preventive benefits and the claim will deny or shift to patient liability depending on modifier/ABN handling. Use the wound/injury diagnosis pathway when -- and only when -- the clinical record supports it.

5. Modifier Usage: 25 and AT (and Medicare Noncovered Logic)

5.1 Modifier 25 belongs on the E/M (when justified)

When an E/M service is provided on the same date as immunization, modifier 25 may be appended to the E/M code only when the E/M is significant and separately identifiable from the vaccination work. AAFP's immunization administration guidance provides the baseline for this principle: routine immunization screening and related minimal services are not, by themselves, a separately billable problem-oriented visit.

• Correct: 99213**-25** + 90715 + 90471 when a distinct medical evaluation is documented.
• Incorrect: Applying -25 to vaccine lines or applying -25 automatically for "shot-only" encounters without a separate assessment/plan.

5.2 Modifier AT for acute treatment (Medicare workflows)

For Medicare tetanus-containing vaccine claims submitted under the injury/wound-care benefit category, some Medicare processing workflows require modifier AT ("acute treatment") on the vaccine and administration lines to indicate the immunization is being provided due to acute injury/exposure rather than routine prevention. The Texas Medical Association's Medicare-facing guidance summarizes this operational expectation and highlights denial risk when AT is omitted. Noridian's billing guideline also operationalizes the wound-care logic and emphasizes documentation and diagnosis specificity.

Do not use AT to "force coverage": AT is appropriate only when the medical record supports acute injury/exposure. Using AT for routine immunization is a mismatch between documentation and claim intent and can create audit exposure.

6. Documentation Standards for Audit-Resistant Billing

For CPT 90715, documentation should be sufficient to answer two payer questions: (1) Did the patient receive the vaccine product billed? (2) Was the administration/coverage pathway billed consistent with the medical record?

6.1 Minimum documentation elements (best practice)

• Vaccine identification: document "Tdap" explicitly (not just "tetanus shot") to support 90715 vs 90714 selection.
• Date and administration route/site: IM injection, anatomic site (e.g., left deltoid).
• Manufacturer/lot/expiration: strongly recommended for immunization integrity and audit defense, and to support product verification when claims are reviewed.
• Administration work: record who administered and that the administration occurred, supporting 90471/90472 or 90460/90461 selection.
• Indication:
  • Routine immunization: record that the encounter is prophylactic/routine (commonly aligns with Z23 logic).
  • Wound care: document the injury, body site, and why tetanus prophylaxis is medically indicated (supports injury ICD-10 and Medicare wound-care coverage logic).

6.2 Documentation for pregnancy vaccination (Tdap each pregnancy)

CDC recommends Tdap during each pregnancy, with optimal timing between gestational weeks 27 through 36, preferably early in that period. Documentation should include gestational age/timing context and that the vaccine was provided per pregnancy vaccination recommendations. This strengthens consistency between the clinical note, the coded service, and preventive coverage expectations in commercial/Medicaid plans.

6.3 Documentation for adult schedule alignment

CDC's adult schedule indicates Td/Tdap boosters over the life course and highlights Tdap during pregnancy. While payers do not require the note to cite CDC, charting that the patient is due per immunization history (and recording the history) is a practical defense against medical necessity questions and helps prevent duplicate vaccination billing.

High-yield audit trigger: "Tetanus shot given" without specifying Tdap vs Td. This forces payers/reviewers to infer whether pertussis was included, which is a preventable ambiguity. Make the product explicit and ensure the billed CPT matches it.

7. Comparison Table: 90715 vs 90714 + Administration and Key Rules

8. Real-World Billing Scenarios

Scenario 1: Medicare wound care (acute injury) with Tdap

Setting: Office/urgent care.

Clinical event: Patient presents with a laceration; clinician documents wound characteristics and tetanus prophylaxis need.

Coding logic: Build the claim around the injury diagnosis (highest specificity). Medicare Part B wound-care pathway requires documentation to support medical necessity and often requires modifier AT on vaccine and administration lines per workflow guidance.

Typical codes: 90715, 90471 (and AT when required by the processing pathway), linked to the injury ICD-10.

Documentation tip: Record body site, laterality when applicable, and the clinical rationale for tetanus prophylaxis. Noridian emphasizes that documentation must support the injury site and vaccination given.

Scenario 2: Routine adult booster (commercial payer)

Setting: Primary care visit or vaccine-only appointment.

Clinical event: Adult is due for booster based on immunization history.

Coding logic: Use Z23 for routine immunization, bill 90715 + 90471. If additional vaccines are given, add 90472 for each additional injection. Administration guidance supports correct use of 90471/90472 for these encounters.

Schedule anchor: CDC's adult schedule reflects Td/Tdap booster patterns and supports the clinical appropriateness of staying up to date.

Scenario 3: Same-day problem visit plus immunization (E/M + vaccine)

Setting: Office visit.

Clinical event: Patient is evaluated for a distinct complaint (e.g., acute condition) and also receives Tdap.

Coding logic: Bill the appropriate E/M code with modifier 25 only if the record supports a separately identifiable evaluation and management service beyond vaccination work; then report 90715 + 90471 for the immunization. AAFP guidance is the operational baseline for appropriate immunization administration billing and E/M separation logic.

Audit-proofing tip: Ensure the note contains a distinct assessment/plan for the problem-oriented visit, not just immunization screening elements.

Scenario 4: Pregnancy vaccination (Tdap during each pregnancy)

Setting: OB clinic or prenatal care setting.

Clinical event: Pregnant patient receives Tdap in the third trimester.

Coding logic: Bill 90715 + 90471, linked to appropriate pregnancy-related diagnosis coding used by your payer workflow (often with Z23 as appropriate for immunization lines depending on payer rules and claim design). The key compliance point is that documentation supports pregnancy context and timing.

Guideline anchor: CDC states Tdap during each pregnancy provides best infant protection, with optimal timing between 27 and 36 weeks gestation.

Scenario 5: Product-code integrity check (Tdap vs Td)

Setting: Any site.

Clinical event: Chart note says "tetanus shot," but does not specify Tdap vs Td.

Coding risk: This ambiguity creates risk that 90715 is billed when Td (90714) was administered, or vice versa.

Resolution: Require staff to document the vaccine name explicitly and reconcile to inventory/lot documentation. The CPT descriptors for both products support accurate code selection.